natgillin/translations-raw huggingface dataset:
Biological effects that may be mediated by Plegridy include up-regulation of anti-inflammatory cytokines (e.g.
Biološki učinci koji mogu biti posredovani Plegridyjem, uključuju povećanu ekspresiju protuupalnih citokina (npr.
Biological response markers (e.g., 2’,5’-OAS activity, neopterin and beta 2-microglobulin) are induced by interferon beta-1a following subcutaneous doses administered to healthy volunteer subjects.
Nakon supkutane primjene doza zdravim dobrovoljcima interferon beta-1a inducira biljege biološkog odgovora (npr. aktivnost 2',5'-oligoadenilat-sintetaze (OAS), neopterin i beta-2 mikroglobulin).
BioMarin Europe Limited 10 Bloomsbury Way London, WC1A 2SL United Kingdom
BioMarin Europe Limited 10 Bloomsbury Way London, WC1A 2SL Ujedinjeno Kraljevstvo
BioMarin Pharmaceutical Inc, Galli Drive Facility, 46 Galli Drive, Novato, CA 94949, USA Name and address of the manufacturer responsible for batch release‌
BioMarin Pharmaceutical Inc, Galli Drive Facility, 46 Galli Drive, Novato, CA 94949, SAD Naziv i adresa proizvođača odgovornog za puštanje serije lijeka u promet
Biopoin
EU/1/09/565/003
Biopoin
EU/1/09/565/005
Biopoin
EU/1/09/565/007
Biopoin
EU/1/09/565/009
Biopoin
EU/1/09/565/011
Biopoin
EU/1/09/565/012
Biopoin
EU/1/09/565/014
Biopoin
EU/1/09/565/015
Biopoin
EU/1/09/565/018
Biopoin
EU/1/09/565/019
Biopoin
EU/1/09/565/020
Biopoin
EU/1/09/565/021
Biopoin
EU/1/09/565/023
Biopoin
EU/1/09/565/041
Biopoin
EU/1/09/565/042
Biopoin
štrcaljki
Biopoin 1,000 IU/0.5 ml
Biopoin 1000 IU/0,5 ml
Biopoin 1,000 IU/0.5 ml solution for injection in pre-filled syringe
Biopoin 1000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki
Biopoin 2,000 IU/0.5 ml
Biopoin 2000 IU/0,5 ml
Biopoin 2,000 IU/0.5 ml solution for injection in pre-filled syringe
Biopoin 2000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki
Biopoin 3,000 IU/0.5 ml
Biopoin 3000 IU/0,5 ml
Biopoin 3,000 IU/0.5 ml solution for injection in pre-filled syringe
Biopoin 3000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki
Biopoin 4,000 IU/0.5 ml
Biopoin 4000 IU/0,5 ml
Biopoin 4,000 IU/0.5 ml solution for injection in pre-filled syringe
Biopoin 4000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki
Biopoin 5,000 IU/0.5 ml
Biopoin 5000 IU/0,5 ml
Biopoin 5,000 IU/0.5 ml solution for injection in pre-filled syringe
Biopoin 5000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki
Biopoin is used for the treatment of anaemia accompanied by symptoms (for example fatigue, weakness and shortness of breath).
Biopoin se koristi u liječenju slabokrvnosti (anemije) praćene simptomima (na primjer, umorom, slabošću ili nedostatkom zraka).
Biopsy specimen – staining pattern
Bioptat – karakteristika obojenja
Biopsy, implant and follow up care
biopsija, implantacija i njega nakon zahvata
Biotranformation
Biotransormacija
Biotransform
Biotransformacija
Biotransformation
NAZIV LIJEKA
Biotransformation
Oštećenje bubrega
Biotransformation (trastuzumab emtansine and DM1)
Biotransformacija (trastuzumab emtanzin i DM1)
Biotransformation and elimination:
Biotransformacija i eliminacija
Biotransformation: Both the liver and the kidney have been shown to be important protein catabolising organs for growth hormone.
Biotransformacija: Pokazalo se da su i jetra i bubrezi važni za katabolizam hormona rasta.
Biotransformation: entecavir is not a substrate, inhibitor or inducer of the CYP450 enzyme system.
Biotransformacija: entekavir nije supstrat, inhibitor niti induktor enzimskog sustava CYP450.
Biotransformation: Erlotinib is metabolised in the liver by the hepatic cytochromes in humans, primarily CYP3A4 and to a lesser extent by CYP1A2.
Biotransformacija: Erlotinib se metabolizira u jetri pomoću jetrenih citokroma u ljudi, prije svega CYP3A4 te nešto manje CYP1A2.
Biotransformation: In man, about 80% of the circulating memantine-related material is present as the parent compound.
Biotransformacija: kod ljudi je oko 80% memantina u cirkulaciji prisutno u nepromijenjenom obliku.
Biotransformation: studies in humans and in vitro studies using human liver microsomes and expressed enzymes have demonstrated that maraviroc is principally metabolized by the cytochrome P450 system to metabolites that are essentially inactive against HIV-1.
Biotransformacija: ispitivanja na ljudima kao i in vitro ispitivanja na humanim mikrosomima jetre i pojedinim enzimskim sustavima pokazala su da se maravirok pretežno metabolizira putem sustava citokroma P450 u metabolite koji su u osnovi inaktivni prema HIV-1.
Bioveta, a.s., Komenského 212,
Komenského 212,
Biphasic dose response of cell growth inhibition was observed.
Opažen je bifazični odgovor na dozu inhibicije staničnog rasta.
Bipolar disorder*
bipolarni poremećaj
Bipolar disorder*, completed suicide*, suicide attempt*, hallucination auditory, hallucination visual, psychiatric decompensation
bipolarni poremećaj*, izvršeno samoubojstvo*, pokušaj samoubojstva*, auditorne halucinacije, vizualne halucinacije, psihička dekompenzacija
Birds infected with MD virus can be carriers and shedders of the virus for life.
Ptice zaražene virusom MD-a mogu biti prijenosnici i nositelji virusa cijeli život.
BiResp Spiromax 160 mcg/4.5 mcg inhalation powder budesonide/formoterol fumarate dihydrate Inhalation use.
BiResp Spiromax 160 μg/4,5 μg prašak inhalata budezonid/formoterolfumarat dihidrat Primjena u dišne putove.
BiResp Spiromax 160 micrograms / 4.5 micrograms inhalation powder
BiResp Spiromax 160 mikrograma/4,5 mikrograma, prašak inhalata
BiResp Spiromax 160 micrograms /4.5 micrograms inhalation powder
BiResp Spiromax 160 mikrograma/4,5 mikrograma prašak inhalata
BiResp Spiromax 160 micrograms/4.5 micrograms, inhalation powder
BiResp Spiromax 160 mikrograma/4,5 mikrograma, prašak inhalata
BiResp Spiromax 320 mcg/9 mcg inhalation powder budesonide/formoterol fumarate dihydrate Inhalation use.
BiResp Spiromax 320 µg/9 µg prašak inhalata. budezonid/ formoterolfumarat dihidrat Primjena u dišne putove
BiResp Spiromax 320 micrograms/9 micrograms, inhalation powder
BiResp Spiromax 320 mikrograma/9 mikrograma prašak inhalata
BiResp Spiromax can also be used to treat the symptoms of severe COPD in adults.
BiResp Spiromax također se može koristiti za liječenje simptoma teškog KOPB-a u odraslih.
BiResp Spiromax has no or negligible influence on the ability to drive and use machines.
BiResp Spiromax ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
BiResp Spiromax is a ‘hybrid medicine’.
BiResp Spiromax je „hibridni lijek”.
BiResp Spiromax is also used to relieve the symptoms of severe chronic obstructive pulmonary disease (COPD) in adults who have had exacerbations (flare–ups) of the disease in the past despite regular treatment.
BiResp Spiromax se također koristi za ublažavanje simptoma zbiljne kronične opstruktivne pulmonalne bolesti (KOPB-a) u odraslih osoba koji imaju eksacerbacije (pogoršanja) bolesti u prošlosti usprkos redovitom liječenju.
BiResp Spiromax is indicated in adults 18 years of age and older only.
BiResp Spiromax indiciran je samo u odraslih u dobi od 18 godina i više.
BiResp Spiromax is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate:
BiResp Spiromax je indiciran u redovitom liječenju astme kad je primjereno kombinirano liječenje (inhalacijskim kortikosteroidom i dugodjelujućim agonistima ß2-adrenergičkih receptora):
BiResp Spiromax is not an appropriate treatment for the adult patient with only mild asthma who is not adequately controlled with an inhaled corticosteroid and “as needed” inhaled short-acting β2 adrenoreceptor agonists.
BiResp Spiromax nije odgovarajuće liječenje za odraslog bolesnika koji ima samo blagi oblik astme i koji nije zadovoljavajuće kontroliran inhalacijskim kortikosteroidom i „prema potrebi“ inhalacijskim ß2 adrenoreceptorskim agonistima kratkog djelovanja.
BiResp Spiromax is NOT indicated for use in children, 12 years of age and younger or adolescents, 13 to 17 years of age.
BiResp Spiromax NIJE indiciran za primjenu u djece s navršenih 12 godina i mlađu niti za adolescente u dobi od 13 do 17 godina.
BiResp Spiromax is not indicated for use in children, 12 years of age and younger or adolescents, 13 to 17 years of age.
BiResp Spiromax nije indiciran za primjenu u djece, u dobi od 12 godina i mlađe, niti za adolescente u dobi od 13 do 17 godina.
BiResp Spiromax is not indicated in children and adolescents under the age of 18 years (see section 4.2).
BiResp Spiromax nije indiciran u djece i adolescenata u dobi manjoj od 18 godina starosti (vidjeti dio 4.2).
BiResp Spiromax maintenance and reliever therapy
Terapija održavanja i terapija ublažavanja akutnih simptoma astme lijekom BiResp Spiromax
BiResp Spiromax should be discontinued immediately, the patient should be assessed and an alternative therapy is instituted if necessary (see section 4.4).
BiResp Spiromax se mora trenutno prekinuti, bolesnika se mora procijeniti , te po potrebi, treba mu uvesti drugu terapiju (vidjeti dio 4.4).
BiResp Spiromax should be discontinued immediately, the patient should be assessed and an alternative therapy is instituted if necessary (see section 4.4).
BiResp Spiromax se mora trenutno prekinuti, bolesnika se mora procijeniti, te po potrebi, treba mu uvesti drugu terapiju (vidjeti dio 4.4).
Birth control based on hormones – such as oral contraceptives or birth control pills, hormone injections, implants, or birth control skin patches don’t reliably prevent pregnancy in women who are taking STAYVEER.
Metoda hormonske kontracepcije npr. uzeta kroz usta, u obliku injekcija, implantata ili flastera nije pouzdana u žena koje uzimaju lijek STAYVEER.
Birth control based on hormones – such as oral contraceptives or birth control pills, hormone injections, implants, or birth control skin patches don’t reliably prevent pregnancy in women who are taking Tracleer.
Metode hormonske kontracepcije primjenjene oralno, u obliku injekcija, implantata ili flastera nisu pouzdane u žena koje uzimaju Tracleer.
birth control medicines (contraceptives) containing hormones, such as pills, injections, or patches
lijekove za sprječavanje trudnoće (kontraceptive) koji sadrže hormone, poput pilula, injekcija ili flastera
Birth control medicines containing hormones (such as pills, injections or patches) may not work as well while you are taking Tafinlar or combination treatment (Tafinlar as well as trametinib).
Lijekovi za sprječavanje trudnoće koji sadrže hormone (poput pilula, injekcija ili flastera) mogu imati oslabljeno djelovanje tijekom uzimanja lijeka Tafinlar ili kombinirane terapije (i Tafinlar i trametinib).
birth control medicines which can include birth control pills, skin patches, implants, and certain Intrauterine devices (IUDs) that release hormones may not work adequately when taken together with EMEND.
redstva za kontrolu začeća, uključujući kontracepcijske tablete, hormonske flastere za kožu, implantate i neke intrauterine uloške koji oslobađaju hormone, mogu slabije djelovati kad se uzimaju zajedno s lijekom EMEND.
birth control medicines which can include birth control pills, skin patches, implants, and certain Intrauterine devices (IUDs) that release hormones may not work adequately when taken together with EMEND.
sredstva za kontrolu začeća, uključujući kontracepcijske tablete, hormonske flastere za kožu, implantate i neke intrauterine uloške koji oslobađaju hormone, mogu slabije djelovati kad se uzimaju zajedno s lijekom EMEND.
birth control medicines which can include birth control pills, skin patches, implants, and certain Intrauterine devices (IUDs) that release hormones may not work adequately when taken together with IVEMEND.
sredstva za kontrolu začeća, uključujući kontracepcijske tablete, hormonske flastere za kožu, implantate i neke maternične uloške koji oslobađaju hormone te mogu imati slabije djelovanje kad se uzimaju zajedno s lijekom IVEMEND.
Birth control using hormones (such as pills, injections or patches) may not work as well if you are taking Mekinist or combination treatment (Mekinist as well as dabrafenib).
Hormonska kontracepcijska sredstva (poput pilula, injekcija ili flastera) možda neće biti jednako djelotvorna dok uzimate Mekinist ili kombiniranu terapiju (Mekinist i dabrafenib).
Birth defects after Assisted Reproductive Technology (ART) may be slightly higher than after spontaneous conceptions.
Prirođena oštećenja nakon metoda potpomognute oplodnje mogu biti blago povećani nego nakon spontanog začeća.
Bisphosphonates (used to treat bone diseases).
bisfosfonata (koji se upotrebljavaju za liječenje koštanih bolesti)
Bitherapy (PegIntron with ribavirin): applies to all adult and paediatric patients 3 years of age and older.
Dvojna terapija (PegIntron s ribavirinom): vrijedi za sve odrasle i pedijatrijske bolesnike u dobi od 3 godine i starije.
Bitherapy (ViraferonPeg with ribavirin): applies to all adult and paediatric patients 3 years of age and older.
Dvojna terapija (ViraferonPeg s ribavirinom): vrijedi za sve odrasle i pedijatrijske bolesnike u dobi od 3 godine i starije.
Bitherapy and monotherapy Summary of the safety profile
Dvojna terapija i monoterapija Sažetak sigurnosnog profila
Bitherapy with peginterferon alfa-2b or interferon alfa-2b
Dvojna terapija s peginterferonom alfa-2b ili interferonom alfa-2b
Bitherapy: The recommended duration of treatment for HCV/HIV co-infected patients is 48 weeks with bitherapy, regardless of genotype.
Dvojna terapija: Preporučeno trajanje liječenja za bolesnike s istodobnom infekcijom HCV-om i HIV-om iznosi 48 tjedana dvojne terapije, bez obzira na genotip.
Bival + GP
Bival + inhibitor GP
Bival alone (N=2,911) %
Samo bival (N=2911)
bivalirudin (N=2,902)
bivalirudin (N=2902)
bivalirudin (N=2,994)
bivalirudin (N=2994)
BL=baseline; SE=standard error of mean
PV=početna vrijednost; SE=standardna pogreška srednje vrijednosti
Black 59 %
Crnci 59
black injection
za injiciranje
Black ink containing Shellac
Crna tinta sadrži: Šelak Propilenglikol
Black ink containing: shellac, black iron oxide (E172), propylene glycol and potassium hydroxide
Crna boja koja sadrži: šelak, crni željezov oksid (E172), propilenglikol i kalijev hidroksid.
Black ink containing: shellac, black iron oxide (E172), propylene glycol and potassium hydroxide
Crna tinta koja sadrži: šelak, crni željezov oksid (E172), propilenglikol i kalijev hidroksid.
Black ink containing: shellac, black iron oxide (E172), propylene glycol and potassium hydroxide.
Crna boja koja sadrži: šelak, željezov oksid, crni (E172), propilenglikol i kalijev hidroksid.
Black ink containing: shellac, black iron oxide (E172), propylene glycol and potassium hydroxide.
Crna tinta koja sadrži: šelak, željezov oksid, crni (E172), propilenglikol i kalijev hidroksid.
Black ink: Shellac, iron oxide black (E172), propylene glycol (E1520)
Tinta za označavanje: šelak, crni željezov oksid (E172), propilenglikol (E1520)
Black iron oxide (E172)
propilenglikol željezov oksid, crni (E172)
Black iron oxide (E172) Potassium hydroxide
propilenglikol željezov oksid, crni (E172) kalijev hidroksid
Black iron oxide (E172) Potassium hydroxide
Šelak propilenglikol željezov oksid, crni (E172) kalijev hidroksid
Black iron oxide (E172) Shellac.
Crni željezov oksid (E172) Šelak.
Black iron oxide (E172) Shellac.
Željezov oksid, crni (E172) Šelak.
Black iron oxide Titanium dioxide Yellow iron oxide
indigo karmin crni željezov oksid titanijev dioksid žuti željezov oksid
Black or African Heritage
crnci ili afričkog podrijetla
black or tar-like stools,
crna stolica ili stolica poput katrana,
black or tarry stools
crna ili katranasta stolica
Black patients (n=80/group) in study 1100.1486 showed approximately 30% higher trough concentrations than Caucasian patients (250-325 patients/group) in both the Viramune immediate-release and Viramune prolonged-release treatment groups over 48 weeks of treatment at 400 mg/day.
Crnci (n=80/skupina) u ispitivanju 1100.1486 pokazali su oko 30 % više koncentracije na kraju dozirnog intervala u odnosu na bijelce (250-325 bolesnika/skupina) i u skupini na Viramuneu s trenutnim oslobađanjem i Viramuneu s produljenim oslobađanjem tijekom 48 tjedana liječenja pri 400 mg/dan.
Black population
Crnačka populacija
Black tarry stools
crnu, katranastu stolicu,
black tarry stools (discoloured bowel movements are a uncommon side effect that may affect up to 1 in 100 people)
crne katranaste stolice (promjena boje stolice je manje česta nuspojava koja se može javiti u do 1 na 100 osoba)
black, tarry, or bloody stools, or coughing up of blood - these may be signs of bleeding inside your body. diarrhoea, feeling and being sick - these are very common side effects that can become serious if they cause you to become dehydrated, which can lead to kidney failure.
crna, katranasta ili krvava stolica ili iskašljavanje krvi – to mogu biti znakovi krvarenja u tijelu proljev, mučnina i povraćanje – to su vrlo česte nuspojave koje mogu postati ozbiljne ako dovedu do dehidracije, koja može uzrokovati zatajenje bubrega.
Black/African American
crna/Afroamerikanci
Black/African American
crna/afroamerička
Black/African American
crnci/afroamerikanci
Bladder
Mokraćni mjehur
bladder and skin infections  sweating
infekcije mjehura i kože  znojenje
bladder cancer
Nuspojava
bladder cancer
rak mokraćnog mjehura
bladder disfunction
poremećaj funkcije mokraćnog mjehura
Bladder disorders
poremećaji mokraćnog mjehura
Bladder disorders
Problemi s mjehurom
bladder infection
infekcija mokraćnog mjehura
Bladder infection (cystitis)
Infekcija mokraćnog mjehura (cistitis)
bladder infections
infekcije mokraćnog mjehura
bladder inflammation with bleeding
upala mokraćnog mjehura s krvarenjem
Bladder irritation
Iritacija mjehura
Bladder obstruction and urinary retention2 Uncommon
Opstrukcija vrata mokraćnog mjehura i urinarna retencija2 Manje često
Bladder or kidney infection, upper respiratory infection, CMV infection (can cause serious blood and tissue infections), fever, cough, bronchitis
Infekcija mokraćnog mjehura ili bubrega, infekcija gornjih dišnih puteva, citomegalovirusna (CMV) infekcija (može prouzročiti ozbiljnu infekciju krvi i tkiva), vrućica, kašalj, bronhitis
Bladder outlet obstruction
opstrukcija pražnjenja mjehura
Bladder pain
Bol mokraćnog mjehura
Blanchardstown Industrial Park Blanchardstown
Blanchardstown Industrial Park
Blast crisis and Ph+
trombociti<50 x 109/l
Blast crisis is defined as blasts ≥ 30 % in blood or bone marrow or extramedullary disease other than hepatosplenomegaly.
Blastična se kriza definira kao blasti 30 % u krvi ili koštanoj srži ili postojanje ekstramedularne bolesti osim hepatosplenomegalije.
Blast crisis is defined as blasts ≥ 30% in blood or bone marrow or extramedullary disease other than hepatosplenomegaly.
Blastična se kriza definira kao blasti30% u krvi ili koštanoj srži ili postojanje ekstramedularne bolesti osim hepatosplenomegalije.
Blast crisis is defined as blasts ≥ 30% in blood or bone marrow or extramedullary disease other than hepatosplenomegaly.
Blastična se kriza definira kao prisutnost 30% blasta u krvi ili koštanoj srži ili postojanje ekstramedularne bolesti osim hepatosplenomegalije.
Blast crisis is the most advanced stage of this disease.
Blastična kriza predstavlja najuznapredovaliji stadij ove bolesti.
Blast free hypoplastic or aplastic bone marrow3
Hipoplastična ili aplastična koštana srž bez blasta3
Blast Phase With prior treatment of at least Imatinib
Blastična faza s prethodnim liječenjem najmanje imatinibom
bleeding
desni
bleeding (at site of infusion or after surgery) nausea
krvarenje (na mjestu infuzije ili nakon operacije) mučnina
bleeding (for example from an operation site, an existing stomach ulcer, nosebleed, bruising)
krvarenje (na primjer na mjestu kirurškog reza, krvarenje postojećeg čira želuca, krvarenje iz nosa, stvaranje modrica)
bleeding (for example from an operation site, an existing stomach ulcer, nosebleed, gums)
krvarenje (na primjer na mjestu kirurškog reza, krvarenje postojećeg čira želuca ili krvarenje iz nosa i desni)
bleeding (haemorrhage)
krvarenje (hemoragija)
Bleeding (haemorrhage), for example in the gut wall
Krvarenje (hemoragija), na primjer u stijenci crijeva
Bleeding (major and minor bleeding including femoral artery access, CABG- related, gastrointestinal, genitourinary, retroperitoneal, intracranial, haematemesis, haematuria, oral/oropharyngeal, haemoglobin/haematocrit decreased and other).
krvarenje (velika i manja krvarenja uključujući i krvarenje na mjestu pristupa femoralnoj arteriji, vezana uz CABG, gastrointestinalno, urogenitalno, retroperitonealno, intrakranijalno krvarenje, hematemeza, hematurija, oralno/orofaringealno krvarenje, pad hemoglobina/hematokrita i drugo)
Bleeding (major and minor bleeding including femoral artery access, CABG-related, gastrointestinal, genitourinary, retroperitoneal, intracranial, haematemesis, haematuria, oral/oropharyngeal, haemoglobin/haematocrit decreased and other).
krvarenje (velika i manja krvarenja uključujući i krvarenje na mjestu pristupa femoralnoj arteriji, vezana uz CABG, gastrointestinalno, urogenitalno, retroperitonealno, intrakranijalno krvarenje, hematemeza, hematurija, oralno/orofaringealno krvarenje, pad hemoglobina/hematokrita i drugo)
bleeding (most commonly nose bleeds, but also other types of bleeding such as blood in the urine, bruising, bleeding from the gums or gut wall)
krvarenja (najčešće iz nosa, ali i druge vrste krvarenja, kao što su krv u mokraći, modrice, krvarenje desni ili iz stijenke crijeva)
bleeding (most commonly nose bleeds, but also other types of bleeding such as blood in the urine, bruising, bleeding from the gums or gut wall)
krvarenja (najčešće iz nosa, ali može uključivati i druge vrste krvarenja, kao što je krv u mokraći, modrice, krvarenje desni ili iz stijenke crijeva)
Bleeding (such as nose bleed or blood in your urine)
krvarenje (poput krvarenja iz nosa ili krvi u mokraći)
Bleeding (WHO Grades 1-4) n (%)
Krvarenje (WHO stupanj 1-4), n (%)
Bleeding a lot from a wound.
Veliko krvarenje iz rane.
bleeding abnormal thickening of the skin.
krvarenje neuobičajeno zadebljanje kože
Bleeding abnormalities, such as ecchymoses, purpura and other haemorrhagic events, such as gastrointestinal or gynaecological bleeding, have been reported rarely with the use of antidepressants with serotonergic effect (SSRIs, SNRIs).
Abnormalnosti povezane s krvarenjem kao što su ekhimoze, purpura i drugi hemoragijski događaji, poput gastrointestinalnog ili ginekološkog krvarenja su rijetko prijavljene uz primjenu antidepresiva sa serotonergičkim učinkom (SSRI-i, SNRI-i).
Bleeding after surgery
krvarenje nakon operacije
Bleeding after surgery or from cuts (for example while shaving) and wounds more than is normal
Krvarenje nakon operacije ili iz posjekotina (na primjer tijekom brijanja) i rana više od normalnog
Bleeding and bruising at the puncture site (after PCI treatment) may be painful.
Krvarenje i nastanak modrica na mjestu uboda (nakon PCI zahvata) može biti bolno.
bleeding around a catheter (if present) into the skin
krvarenje na mjestu ulaska katetera (ako je postavljen) u kožu
Bleeding around the heart, in the abdomen, the brain or the eyes, under the skin, from the nose or as coughed up blood
krvarenje oko srca, u trbuhu, mozgu, očima, potkožno ili iz nosa te iskašljavanje krvi
Bleeding associated with a reduction in haemoglobin of at least 20 g/L or leading to a transfusion of at least 2 units of blood or packed cells.
Krvarenje povezano sa smanjenjem hemoglobina od najmanje 20 g/L ili koje zahtjeva transfuziju najmanje 2 jedinice krvi ili ispranih eritrocita.
Bleeding at puncture site
krvarenje na mjestu
Bleeding at puncture site
krvarenje na mjestu punkcije
Bleeding at puncture site
retroperitone- alno krvarenje
bleeding at the injection or puncture site
krvarenje na mjestu uboda injekcije ili punkcije
bleeding at the injection site redness of the eye
krvarenje na mjestu primjene injekcije
Bleeding at the injection site, e.g. blood blister (haematoma)
krvarenje na mjestu davanja injekcije, npr. krvavi podljev (hematom)
Bleeding at the puncture site
krvarenje na mjestu uboda